SEC Form SC 13G/A filed by Zai Lab Limited (Amendment)

2/9/24 10:05:20 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ZLAB alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.6 ZAI LAB LTD COMMON STOCK Cusip #G9887T116 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #G9887T116 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 34,691,087 Item 6: 0 Item 7: 34,692,847 Item 8: 0 Item 9: 34,692,847 Item 11: 3.510% Item 12: HC Cusip #G9887T116 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 34,692,847 Item 8: 0 Item 9: 34,692,847 Item 11: 3.510% Item 12: IN Item 1(a). Name of Issuer: ZAI LAB LTD Item 1(b). Address of Issuer's Principal Executive Offices: 4560 JINKE ROAD, BLDG. 1, 4F, PUDONG SHANGHAI, F4 201210 CHINA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: G9887T116 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 34,692,847 (b) Percent of Class: 3.510% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 34,692,847 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ZAI LAB LTD. No one other person's interest in the COMMON STOCK of ZAI LAB LTD is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research (Hong Kong) Limited IA Fidelity Management & Research (Japan) Limited IA Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK FMR Investment Management (UK) Limited FI Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ZAI LAB LTD at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $ZLAB alert in real time by email

Recent Analyst Ratings for

$ZLAB

Date	Price Target	Rating	Analyst
3/7/2025	$55.00	Sector Outperform	Scotiabank
3/3/2025	$29.00 → $36.10	Buy → Neutral	BofA Securities
12/14/2023	$47.50	Overweight	Morgan Stanley
8/10/2023	$70.00	Overweight	Cantor Fitzgerald
3/2/2022	$194.00 → $102.00	Outperform	SVB Leerink
1/21/2022	$64.00	Outperform	Macquarie
12/15/2021	$189.00 → $136.00	Overweight	JP Morgan
11/11/2021	$222.00 → $217.00	Buy	Citigroup

More analyst ratings

SEC Form SC 13G/A filed by Zai Lab Limited (Amendment)

2/9/24 10:05:20 AM ET

$ZLAB

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ZLAB alert in real time by email

Recent Analyst Ratings for

$ZLAB

Date	Price Target	Rating	Analyst
3/7/2025	$55.00	Sector Outperform	Scotiabank
3/3/2025	$29.00 → $36.10	Buy → Neutral	BofA Securities
12/14/2023	$47.50	Overweight	Morgan Stanley
8/10/2023	$70.00	Overweight	Cantor Fitzgerald
3/2/2022	$194.00 → $102.00	Outperform	SVB Leerink
1/21/2022	$64.00	Outperform	Macquarie
12/15/2021	$189.00 → $136.00	Overweight	JP Morgan
11/11/2021	$222.00 → $217.00	Buy	Citigroup

More analyst ratings

SEC Form SC 13G/A filed by Zai Lab Limited (Amendment)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$ZLAB

SEC Form SC 13G/A filed by Zai Lab Limited (Amendment)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$ZLAB

$ZLAB
SEC Filings

SEC Form SCHEDULE 13G filed by Zai Lab Limited

SEC Form 144 filed by Zai Lab Limited

Amendment: SEC Form SCHEDULE 13G/A filed by Zai Lab Limited

$ZLAB
Analyst Ratings

Scotiabank initiated coverage on Zai Lab with a new price target

Zai Lab downgraded by BofA Securities with a new price target

Morgan Stanley initiated coverage on Zai Lab with a new price target

$ZLAB
Press Releases

Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer

Zai Lab Establishes Oncology Scientific Advisory Board

Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates

$ZLAB
Insider Purchases

Smiley Joshua L bought $64,200 worth of American Depositary Shares (3,000 units at $21.40), increasing direct ownership by 10% to 31,684 units (SEC Form 4)

Smiley Joshua L bought $62,490 worth of American Depositary Shares (3,000 units at $20.83), increasing direct ownership by 15% to 23,527 units (SEC Form 4)

Smiley Joshua L bought $119,600 worth of American Depositary Shares (4,000 units at $29.90), increasing direct ownership by 24% to 20,527 units (SEC Form 4)

$ZLAB
Insider Trading

Officer Smiley Joshua L converted options into 15,900 units of American Depositary Shares and sold $240,643 worth of American Depositary Shares (6,641 units at $36.24), increasing direct ownership by 14% to 76,604 units (SEC Form 4)

Chief Legal Officer Edmondson Frazor Titus Iii converted options into 4,850 units of American Depositary Shares and sold $68,232 worth of American Depositary Shares (1,883 units at $36.24), increasing direct ownership by 8% to 42,065 units (SEC Form 4)

Chief Financial Officer Chen Yajing converted options into 1,250 units of American Depositary Shares and sold $50,932 worth of American Depositary Shares (1,438 units at $35.42), decreasing direct ownership by 1% to 16,720 units (SEC Form 4)

$ZLAB
Leadership Updates

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

Zai Lab Appoints Michel Vounatsos To Its Board of Directors

Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

$ZLAB
Financials

Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates

Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

$ZLAB
Large Ownership Changes

SEC Form SC 13G filed by Zai Lab Limited

Amendment: SEC Form SC 13G/A filed by Zai Lab Limited